What is vWD in dogs?

What is vWD in dogs? - briefly

Von Willebrand disease (vWD) in dogs is an inherited bleeding disorder caused by a deficiency or abnormality of von Willebrand factor (vWF), a protein crucial for blood clotting. This condition can lead to prolonged bleeding times and may result in excessive blood loss during surgery, trauma, or estrus.

What is vWD in dogs? - in detail

Von Willebrand disease (vWD) is a hereditary bleeding disorder that affects dogs, similar to hemophilia in humans. The disease is named after Finnish physician Erik von Willebrand, who first described it in humans in 1926. In dogs, vWD is caused by a deficiency or dysfunction of von Willebrand factor (vWF), a protein that plays a crucial role in blood clotting.

vWF serves multiple functions in the coagulation cascade. It facilitates platelet adhesion to the damaged endothelium, acts as a carrier for coagulation factor VIII, and promotes platelet aggregation. In dogs with vWD, the abnormal or insufficient vWF leads to impaired primary hemostasis, resulting in prolonged bleeding times after injury or surgery.

There are three types of vWD in dogs, classified based on the severity of the vWF defect:

  1. Type 1: This is the most common form of vWD in dogs, accounting for approximately 70-80% of all cases. Dogs with type 1 vWD have a quantitative deficiency of vWF, meaning they produce less than normal amounts of the protein. The bleeding tendency in these dogs is usually mild to moderate and may only become apparent after trauma or surgery.

  2. Type 2: Type 2 vWD is less common than type 1, making up about 20-30% of all cases. In this form, the vWF produced by the dog is qualitatively abnormal, meaning it does not function properly despite being present in normal or near-normal amounts. The bleeding tendency in dogs with type 2 vWD can be more severe than in those with type 1, as the defective vWF impairs multiple aspects of primary hemostasis.

  3. Type 3: This is the most severe form of vWD and is quite rare in dogs. Dogs with type 3 vWD have a complete absence of functional vWF, leading to a significant bleeding tendency that may manifest as spontaneous hemorrhages or prolonged bleeding after minor injuries.

The clinical signs of vWD in dogs can vary depending on the severity of the disease and the degree of trauma or surgery. Common symptoms include:

  • Prolonged bleeding from wounds, surgical sites, or after tooth extraction
  • Nosebleeds (epistaxis)
  • Bleeding from the gums (gingival bleeding)
  • Blood in the urine or stool (hematuria or melena)
  • Bruising or hematomas under the skin
  • Spontaneous internal hemorrhages, such as those affecting the joints, muscles, or abdominal organs

The diagnosis of vWD in dogs typically involves a combination of clinical evaluation, laboratory testing, and genetic analysis. The most commonly used diagnostic tests include:

  1. BuCCo time (BCT): This test measures the time it takes for a blood sample to clot after activation by calcium and a platelet-activating agent. In dogs with vWD, the BCT is usually prolonged due to the impaired primary hemostasis.
  2. vWF antigen (vWF:Ag): This test quantifies the amount of vWF present in the dog's blood. Low levels of vWF:Ag are indicative of type 1 or type 3 vWD, while normal or elevated levels suggest type 2 disease.
  3. Genetic testing: Molecular analysis of the vWF gene can help identify specific mutations associated with vWD in dogs. This information is particularly useful for breeding purposes and determining carrier status in related dogs.

The treatment of vWD in dogs depends on the severity of the disease and the specific clinical situation. In mild cases, no treatment may be necessary, as the dog's natural clotting mechanisms can compensate for the vWF deficiency. However, in more severe cases or during surgical procedures, several therapeutic options are available:

  1. Desmopressin (DDAVP): This synthetic analog of vasopressin stimulates the release of stored vWF from endothelial cells, temporarily increasing the levels of functional vWF in the bloodstream. DDAVP is often used to manage bleeding episodes or prevent excessive blood loss during surgery in dogs with vWD.
  2. vWF concentrate: In some cases, purified human or canine vWF concentrates may be administered to dogs with severe vWD. These products contain functional vWF and can help improve clotting times and reduce bleeding tendencies. However, their use should be guided by a veterinarian experienced in the management of coagulation disorders.
  3. Blood transfusions: In emergency situations, blood transfusions may be necessary to stabilize a dog with severe vWD and life-threatening hemorrhages. The use of fresh frozen plasma (FFP) or whole blood containing functional vWF can help temporarily restore hemostasis in these cases.

In conclusion, von Willebrand disease is a significant hereditary bleeding disorder in dogs that affects the body's ability to form clots. By understanding the underlying mechanisms and available diagnostic and therapeutic options, veterinarians and dog owners can work together to manage this condition effectively and minimize its impact on the animal's quality of life.

  • 👤 Author admin.
  • ⏱ Date of published 2025-01-03 13:43.
  • 🖍 Date latest changes 2025-09-03 01:33.
  • 👁 Count views 33.